Gilead’s Seladelpar gets European Marketing Authorization for liver disease treatment
Gilead Sciences (GILD) said on Friday that the European Commission (EC) granted conditional marketing authorization for ...
The Pharma Letter4d
Seladelpar wins conditional EC approval for rare liver disease
Gilead Sciences’ seladelpar has won conditional marketing authorization to treat primary biliary cholangitis (PBC) alongside ...
Zacks.com on MSN13d
GILD Stock Up on Q4 Earnings and Sales Beat & Upbeat '25 Guidance
Gilead Sciences, Inc. GILD reported better-than-expected fourth-quarter results and provided an upbeat guidance for 2025.
The Pharma Letter23d
Parkinson’s disease market across 7MM to grow $7.9 billion in 2033
The market for Parkinson’s disease (PD) drugs across the seven major geographies (7MM; USA, France, Germany, Italy, UK and Japan) is projected to grow at a compound annual growth rate (CAGR) of 8.9% ...
rarediseaseadvisor26d
Seladelpar Leads to Clinically Meaningful Improvements in PBC
52.2% of patients met the composite endpoint of the study. Seladelpar can result in clinically meaningful improvements in markers of cholestasis and liver injury in patients with primary biliary ...
Le Lézard28d
TDA Research AND Mantel Technologies Announce the Launch of TDA'S Canine Decontamination Kit exclusively distributed by Mantel Technologies
TDA's Canine Decontamination Kit is exclusively available from Mantel Technologies. This kit provides a safe and effective means of decontaminating dogs exposed to toxic substances. TDA Research ...
Le Lézard28d
Ambulatory Care Nurses Week: A Nationwide Tribute to Nursing Excellence
PITMAN, N.J., Jan. 28, 2025 /PRNewswire/ -- The American Academy of Ambulatory Care Nursing (AAACN) invites nurses, health care organizations, and communities nationwide to celebrate Ambulatory ...